Search

Your search keyword '"Moride, Yola"' showing total 421 results
Start Over Author "Moride, Yola" Search Limiters Peer Reviewed
421 results on '"Moride, Yola"'

23. Hemolytic Markers, Mortality, and Thromboembolic Events in Cold Agglutinin Disease (CAD): A Retrospective Analysis of the Optum Electronic Health Record Database in the United States

Author

Broome, Catherine M., primary, Barcellini, Wilma, additional, Roeth, Alexander, additional, Karaouni, Alia, additional, Joly, Florence, additional, Yoo, Ronnie, additional, Terlinden, Augustin, additional, Adeyemi, Ayo, additional, Moride, Yola, additional, and Hill, Quentin A., additional

Published
2022
Full Text
View/download PDF

32. Predictors of Pain Reduction Among Fibromyalgia Patients Using Medical Cannabis: A Long‐TermProspective Cohort Study

Author

Sotoodeh, Romina, Waldman, Lilach Eyal, Vigano, Antonio, Moride, Yola, Canac‐Marquis, Michelle, Spilak, Tristan, Gamaoun, Rihab, Kalaba, Maja, Hachem, Yasmina, Beaulieu, Pierre, Desroches, Julie, Ware, Mark A., Perez, Jordi, Shir, Yoram, Fitzcharles, Mary‐Ann, and Martel, Marc O.

Abstract

Many patients with fibromyalgia (FM) report using cannabis as a strategy to improve pain. Given that pain often co‐occurs with symptoms of anxiety and depression (i.e., negative affect) and sleep problems among patients with FM, improvements in these symptoms might indirectly contribute to reductions in pain intensity following cannabis use. The main objective of the study was to examine whether changes in pain intensity following initiation of medical cannabis among patients with FM could be attributed to concurrent changes (i.e., reductions) in negative affect and sleep problems. This was a 12‐month prospective cohort study among patients with FM (n = 323) initiating medical cannabis under the care of physicians. Patients were assessed at baseline, and follow‐up assessment visits occurred every 3 months after initiation of medical cannabis. Patients’ levels of pain intensity, negative affect, and sleep problems were assessed across all visits. Multilevel mediation analyses indicated that reductions in patients’ levels of pain intensity were partly explained by concurrent reductions in sleep problems and negative affect (both P< 0.001). This remained significant even when accounting for patients’ baseline characteristics or changes in medical cannabis directives over time (all P> 0.05). Our findings provide preliminary insight into the potential mechanisms of action underlying pain reductions among patients with FM who are using medical cannabis. Given the high attrition rate (i.e., 75%) observed in the present study at 12 months, our findings cannot be generalized to all patients with FM who are using medical cannabis.

Published
2023
Full Text
View/download PDF

35. Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review.

Author

Castillon, Genaro, Chang, Shun-Chiao, and Moride, Yola

Subjects
GAUCHER'S disease, DISEASE prevalence, LITERATURE reviews, RARE diseases, CROSS-sectional method
Abstract

Incidence and prevalence estimates for Gaucher disease (GD) are scarce for this rare disease and can be variable within the same region. This review provides a qualitative synthesis of global GD incidence and prevalence estimates, GD1–3 type-specific and overall, published in the last 10 years. A targeted literature search was conducted across multiple databases from January 2011 to September 2020, including web-based sources and congress proceedings to May 2021. Searches yielded 490 publications, with 31 analyzed: 20 cohort studies (15 prospective, 5 retrospective), 6 cross-sectional studies, 5 online reports (most from Europe (n = 11) or North America (n = 11); one multiregional). Across all GD types, incidence estimates ranged 0.45–25.0/100,000 live births (16 studies), lowest for Asia-Pacific. Incidence of GD1: 0.45–22.9/100,000 live births (Europe and North America) and GD3: 1.36/100,000 live births (Asia-Pacific only). GD type-specific prevalence estimates per 100,000 population were GD1: 0.26–0.63; GD2 and GD3: 0.02–0.08 (Europe only); estimates for GD type unspecified or overall ranged 0.11–139.0/100,000 inhabitants (17 studies), highest for North America. Generalizability was assessed as "adequate"or "intermediate" for all regions with data. GD incidence and prevalence estimates for the last 10 years varied considerably between regions and were poorly documented outside Europe and North America. Data for GD2 and GD3 were limited. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Encounter Databases

Author

Gerhard, Tobias, primary, Moride, Yola, additional, Pottegård, Anton, additional, and Pratt, Nicole, additional

Published
2021
Full Text
View/download PDF

50. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis

Author

Plattel, Wouter J., primary, Bergamasco, Aurore, additional, Trinchese, Fabrizio, additional, Gavini, François, additional, Bent-Ennakhil, Nawal, additional, Zomas, Athanasios, additional, Castillon, Genaro, additional, Arredondo-Bisono, Teigna, additional, Cristarella, Tiffany, additional, Moride, Yola, additional, and von Tresckow, Bastian, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results